Association of Mineralocorticoid Receptor Antagonists With the Mortality and Cardiovascular Effects in Dialysis Patients: A Meta-analysis
Why the study?
Whether mineralocorticoid receptor antagonists reduce mortality and cardiovascular effects in dialysis patients remains unclear.
Do mineralocorticoid receptor antagonists reduce mortality and improve cardiovascular outcomes in dialysis patients?
Population
Dialysis patients
Comparison
MRA vs placebo or control
Design
Meta-analysis
Authors
Discussion
Loading...
Member takes
Implication
MRA may reduce mortality in dialysis patients without raising potassium; extends evidence to ESRD but low-certainty data leaves practice change open.
Structured PICO
Do mineralocorticoid receptor antagonists reduce mortality and improve cardiovascular outcomes in dialysis patients?
P
Population
Dialysis patients
I
Intervention
Mineralocorticoid receptor antagonists (MRA)
C
Comparator
Placebo or control
O
Outcome
All-cause mortality (ACM) and cardiovascular mortality (CVM)hard clinical
In dialysis patients, MRA therapy provides significant survival and cardiovascular benefits without increasing the risk of hyperkalemia.
Cite This Study
Gou et al. (2022) studied this question.